Liver function test (SGPT) abnormality in 319 confirmed COVID-19 cases in Bangladesh

Abstract

Abstract Background Deranged liver function abnormalities are well-recognized sequela of COVID-19 infection. Globally, there are studies dedicated to evaluate spectrum of liver injury by COVID-19. In this study, we have described the impact of COVID-19 on liver function tests in 319 confirmed COVID cases in Bangladesh. Our study aimed to determine the liver function alteration by COVID-19 in our population. Methods This study included all adult inpatients (> 18 years old) with laboratory-confirmed (RT-PCR) COVID-19 from March to April, 2020 in a tertiary COVID-dedicated hospital. We assessed liver function test and categorized patients according to COVID severity. This was a single-center, retrospective, observational study. Results Among 319 patients with COVID-19, 36% had normal and 64% had abnormal liver function test. Out of this, 18% had 1–2 times, 42% had 2–3 times, and 19% had > 3 times upper limit of normal SGPT during admission. Fifty-seven (18%) patients presented with mild illness, 83 (26%) with moderate, 124 (39%) patients with severe, and 54 (17%) with critical COVID-19 during admission. Significant correlation was found between severity of COVID-19 and raised SGPT level. Conclusion More than half of patients presented during admission with abnormal liver function. COVID-19 has a significant impact on liver function derangement in this population.

Keywords

• Hepatitis
• COVID-19
• Liver function test
• SGPT
• ALT